• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
  • Skip to footer

Biolocity

Emory and Georgia Tech

  • Home
  • Funding
    • Application
  • Lab2Launch
  • Programs
    • Program History
  • Team
    • Oversight Committee
  • Success Stories
    • Funded Projects
    • Testimonials
  • Recent News
  • DRIVe
  • Legal Office Hours
  • B2MTalks
  • Events
    • Resources
You are here: Home / Commercialization / SIRPant Immunotherapeutics, Inc. received FDA clearance and IND application for their novel macrophage therapy (SIRPant-M)

May 2, 2023 by aheard6

SIRPant Immunotherapeutics, Inc. received FDA clearance and IND application for their novel macrophage therapy (SIRPant-M)

SIRPant Immunotherapeutics, Inc

SIRPant Immunotherapeutics, Inc., a Biolocity portfolio company, has achieved a significant milestone in the field of immunotherapy. The company recently announced the FDA clearance of its Investigational New Drug (IND) application for SIRPant-M™, an autologous SIRPαlow activated macrophage immunotherapy. This exciting development marks a major step forward in the advancement of personalized and targeted treatments.

To learn more, visit the official announcement on SIRPant Immunotherapeutics’ website: https://sirpantimmunotx.com/news/sirpant-immunotherapeutics-announces-fda-clearance-of-ind-application-for-sirpant-m-autologous-sirp%ce%b1low-activated-macrophage-immunotherapy/.

Filed Under: Commercialization, News, Technology

Reader Interactions

Primary Sidebar

Footer

Connect with us

  • Email
  • Facebook
  • LinkedIn
  • Twitter

Keep In Touch

Register here to receive our emails on upcoming events and funding opportunities.

Copyright © 2023 · Executive Pro on Genesis Framework · WordPress · Log in